anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pregnancy Category C - There are no adequate and well-controlled studies in pregnant women. Tacrolimus is transferred across the placenta. The use of tacrolimus during pregnancy in humans has been associated with neonatal hyperkalemia and renal dysfunction. Tacrolimus given orally to pregnant rabbits at 0.5 to 4.3 times the clinical dose and pregnant rats at 0.8 to 6.9 times the clinical dose was associated with an increased incidence of fetal death in utero, fetal malformations (cardiovascular, skeletal, omphalocele, and gallbladder agenesis) and maternal toxicity. Tacrolimus should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. 

In pregnant rabbits, tacrolimus at oral doses of 0.32 and 1.0 mg/kg, 0.5 to 4.3 times the clinical dose range (0.075 – 0.2 mg/kg) based on body surface area, was associated with maternal toxicity as well as an increased incidence of abortions. At the 1 mg/kg dose, fetal rabbits showed an increased incidence of malformations (ventricular hypoplasia, interventricular septal defect, bulbous aortic arch, stenosis of ductus arteriosus, interrupted ossification of vertebral arch, vertebral and rib malformations, omphalocele, and gallbladder agenesis) and developmental variations. In pregnant rats, tacrolimus at oral doses of 3.2 mg/kg, 2.6 to 6.9 times the clinical dose range was associated with maternal toxicity, an increase in late resorptions, decreased numbers of live births, and decreased pup weight and viability. Tacrolimus, given orally to pregnant rats after organogenesis and during lactation at 1.0 and 3.2 mg/kg, 0.8 to 6.9 times the recommended clinical dose range was associated with reduced pup weights and pup viability (3.2 mg/kg only); among the high dose pups that died early, an increased incidence of kidney hydronephrosis was observed.
FIELD: medicine. SUBSTANCE: L-ascorbic acid is used as reagent 1. a-glucozyl saccharide being chosen of group which contains: maltoligo saccharide, product of partially hydrolysis of starch, starch being converted into liquid, jelly-like starch, soluble starch or their mixture and having concentration 0.5-30 times more than concentration of L-ascorbic acid is used as reagent 2. Saccharide being chosen of group which contains cyclomaltodextrine glucotransferase and a-glucosidase is used as reagent 3. Said saccharide enables to transfer ferment at pH 3-9 and 20-80 C, presence of glucoamilase being possible. Desired product is prepared by crystallization of supersaturated solution in the presence of seed, its quantity being 0.1-10 mass EFFECT: improves quality of desired product. 5 cl, 1 tbl
Because of the risks of cardiac and local toxicity associated with intravenous phenytoin, oral phenytoin should be used whenever possible. In adults, a loading dose of 10 to 15 mg/kg should be administered slowly. The rate of intravenous administration should not exceed 50 mg per minute in adults and 1 to 3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients. Slower administration rates are recommended to minimize the cardiovascular adverse reactions. Continuous monitoring of the electrocardiogram, blood pressure, and respiratory function is essential.

The loading dose should be followed by maintenance doses of oral or intravenous phenytoin every 6 to 8 hours.

Ordinarily, Phenytoin Sodium Injection should not be given intramuscularly because of the risk of necrosis, abscess formation, and erratic absorption. If intramuscular administration is required, compensating dosage adjustments are necessary to maintain therapeutic serum levels. An intramuscular dose 50% greater than the oral dose is necessary to maintain these levels. When returned to oral administration, the dose should be reduced by 50% of the original oral dose for one week to prevent excessive serum levels due to sustained release from intramuscular tissue sites.

Monitoring serum levels would help prevent a fall into the subtherapeutic range. Serum blood level determinations are especially helpful when possible drug interactions are suspected.
A trigger points is composed of numerous so-called contraction knots. An individual contraction knot appears as a segment of a muscle fiber with extremely contracted sarcomeres and an increased diameter. 2 Trigger point can occur in a number of muscles but they are most common in rhomboid and trapezius muscles. The trapezius is a large paired trapezoid-shaped surface muscle that extends longitudinally from the occipital bone to the lower thoracic vertebrae of the spine and laterally to the spine of the scapula. The trapezius has three functional parts: upper, middle and inferiorfinding typically associated with a trigger point. 5 Active trigger point is any point that causes tenderness and referral pain pattern on palpation. Almost always central trigger points are active and some satellite trigger points are also active. Active trigger points usually produce referred pain and tenderness. In contrast, latent trigger points are foci of hyperirritability in a taut band of muscle, which are clinically associated with a local twitch response, tenderness and referred pain upon manual examination A researcher assessed in 2017, the immediate neurophysiological and clinical effects of DN in patients with upper trapezius MTrPs. The results of this study showed that one session of DN targeting active MTrPs appears to reduce hyperactivity of the sympathetic nervous system and irritability of the motor endplate. DN seems effective at improving symptoms and deactivating active MTrPs.

A study was conducted by Aleksandra k et al in 2018 that aimed to assess the effects of compression trigger point therapy on the stiffness of the trapezius muscle in professional basketball players. Study confirmed that a single treatment session of active myofascial trigger points with ischemic compression causes a decrease in muscle stiffness of the upper portion of the trapezius muscle. A decrease of muscle stiffness has been suggested to improve deficits in range of motion and thereby lower the risk of injuries among baseball players.

The patient's total session of treatment will be 4 weeks. The date will be collected by using questionnaire Neck disability index and Numerical pain rating scale. The number of patients will be randomly allocated 72 patients and 36 patients in each group. And they will be given session of dry needling and ischemic compression in 3 alternate days in a week. Results will be noted immediate after the treatment session then again note the response 3 days after treatment session and ultimately note the response 1 month after the treatment session
The invention discloses application of nano activated carbon sol to preparation of medicine for treating eczema. The particle size of activated carbon in nano activated carbon sol is 1-100 nm. The mass concentration of nano activated carbon in nano activated carbon sol is smaller than or equal to 10%o. The surface of nano activated carbon is modified by carboxyl functional groups. The nano activated carbon sol is used for preparing medicine for treating skin diseases caused by eczema. The nano activated carbon sol has the anti-inflammatory, anti-swelling, antiallergic, itching-relieving and antimicrobial effects and pharmacologic effects related to acute eczema and dermatitis treatment, and has the advantages that healing is quick and the disease course is shortened, relapse does not occur after healing, a big progress is made medically, and the nano activated carbon sol has great clinical application value and practical significance.
Those assigned to the MC control group will be asked to not work with another therapist or seek additional treatment for insomnia-related difficulties during the 6-week MC period. They will be called every other week to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MC participants will also be given contact information to use in case of worsening of symptoms or increasing distress. At the end of six weeks, they will complete the baseline assessments again, which will serve as the post-treatment assessment for the MC period. They will then be randomly assigned to either the CBTi or ICBTi groups.
BACKGROUND: Following an acute myocardial infarction (AMI), surgery for left ventricular free wall rupture (LVFWR) and ventricular septal rupture (VSR) has a high in-hospital mortality rate, which has not improved significantly over time. Unloading the LV is critical to preventing excessive stress on the repair site and avoiding problems such as bleeding, leaks, patch dehiscence, and recurrence of LVFWR and VSR because the tissue is so fragile. We present two cases of patients who used Impella 5.5 for LV unloading following emergency surgery for AMI mechanical complications.
CASE PRESENTATION: A 76-year-old male STEMI patient underwent fibrinolysis of the distal right coronary artery. Three days later, he passed out and went into shock. Echocardiography revealed a cardiac tamponade. We found an oozing-type LVFWR on the posterolateral wall and treated it with a non-suture technique using TachoSil. Before the patient was taken off CPB, Impella 5.5 was inserted into the LV via a 10 mm synthetic graft connected to the right axillary artery. We kept the flow rate above 4.0 to 4.5 L/min until POD 3 to reduce LV wall tension while minimizing pulsatility. On POD 6, we weaned the patient from Impella 5.5. A postoperative cardiac CT scan showed no contrast leakage from the LV. However, a cerebral hemorrhage on POD 4 during heparin administration complicated his hospitalization. Case 2: A diagnosis of cardiogenic shock caused by STEMI occurred in an 84-year-old male patient, who underwent PCI of the LAD with IABP support. Three days after PCI, echocardiography revealed VSR, and the patient underwent emergency VSR repair with two separate patches and BioGlue applied to the suture line between them. Before weaning from CPB, we implanted Impella 5.5 in the LV and added venoarterial extracorporeal membrane oxygenation (VA-ECMO) support for right heart failure. The postoperative echocardiography revealed no residual shunt.
CONCLUSIONS: Patients undergoing emergency surgery for mechanical complications of AMI may find Impella 5.5 to be an effective tool for LV unloading. The use of VA-ECMO in conjunction with Impella may be an effective strategy for managing VSR associated with concurrent right-sided heart failure.
Infrapatellar Approach Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an infrapatellar incision using either a medial parapatellar approach or a transpatellar approach. The knee will then be scanned using T1Rho MRI at 2 weeks postoperatively and 6 months postoperatively.
BACKGROUND: The selection of adequate indicators of tissue hypoxia for guiding the resuscitation process of septic patients is a highly relevant issue. Current guidelines advocate for the use of lactate as sole metabolic marker, which may be markedly limited, and the integration of different variables seems more adequate. In this study, we explored the metabolic profile and its implications in the response to the administration of a fluid challenge in early septic shock patients.
METHODS: Observational study including septic shock patients within 24 h of ICU admission, monitored with a cardiac output estimation system, with ongoing resuscitation. Hemodynamic and metabolic variables were measured before and after a fluid challenge (FC). A two-step cluster analysis was used to define the baseline metabolic profile, including lactate, central venous oxygen saturation (ScvO2), central venous-to-arterial carbon dioxide difference (PcvaCO2), and PcvaCO2 corrected by the difference in arterial-to-venous oxygen content (PcvaCO2/CavO2).
RESULTS: Seventy-seven fluid challenges were analyzed. Cluster analysis revealed two distinct metabolic profiles at baseline. Cluster A exhibited lower ScvO2, higher PcvaCO2, and lower PcvaCO2/CavO2. Increases in cardiac output (CO) were associated with increases in VO2 exclusively in cluster A. Baseline isolated metabolic variables did not correlate with VO2 response, and changes in ScvO2 and PcvaCO2 were associated to VO2 increase only in cluster A.
CONCLUSIONS: In a population of early septic shock patients, two distinct metabolic profiles were identified, suggesting tissue hypoxia or dysoxia. Integrating metabolic variables enhances the ability to detect those patients whose VO2 might increase as results of fluid administration.
FIELD: medicine, pharmacy technology. SUBSTANCE: mercuric chloride is dissolved in whey where sucrose (27-33 g/l) is added preliminary. Then the prepared solution is heated in water bath at 35-45 C for 15-20 min. After heating mixture is kept at 5-10 C for 4-6 days. Preparation shows the expressed cytostatic effect on tumor cultures and immunotropic action with regard to cellular reaction "transplant against host". Preparation stimulates lymphocytes against foreign cells and cells of the same genotype but located in other organism. EFFECT: improved method of preparing, enhanced effectiveness of preparation.
Adding a volume of Sodium Bicarbonate Inj., 8.4% USP Neutralizing Additive Solution to Lidocaine w/ Epinephrine solution such that the pH of the Lidocaine w/ Epinephrine is raised above physiologic pH may cause anesthetic to precipitate out of solution, reducing the clinical effectiveness of the anesthetic. See, e.g., Mulroy MF, Regional Anesthesia, An Illustrated Procedural Guide, 3rd Ed. 2002 (Lippincott Williams and Wilkins, Philadelphia, PA). In addition, solutions that contain precipitate should not be injected.  
  
Adding a volume of Sodium Bicarbonate Inj., 8.4% USP Neutralizing Additive Solution to Lidocaine w/ Epinephrine solution such that the pH of the Lidocaine w/ Epinephrine is raised well above (7.8) physiologic pH may cause tissue irritation when the solution is injected. See Whitcomb M, et al, A Prospective Randomized, Double Blind Study of the Anesthetic Efficacy of Sodium Bicarbonate Buffered 2% Lidocaine with 1:100,000 Epinephrine in Inferior Alveolar Nerve Blocks, Anesth Prog, vol 57, p 59 (2010).
The invention relates to acid-sensitive group modified visco-inert nano particles, a preparation method and application thereof. Selecting mesoporous silica nano particles (MSNs-NH)  2  ) As starting particles. The highly hydrophilic zwitterionic polymer polycarboxybetaine methacrylate (pCBMA) is grafted to MSNs-NH by atom transfer radical polymerization  2  The surface is used for improving the anti-mucus adsorption capacity of the nano particles. And then modifying the acid sensitive group DMMA on the surface of the nano particle through reaction with amino on the surface of the nano particle to obtain the visco-inert nano particle MSNs-pCBMA-DMMA with pH response capability. The nano particles prepared by the method can be incubated by a weak acid environment of a mucus layer and can quickly penetrate through the mucus layerThe surface of the liquid layer is changed from near neutrality to stronger electropositivity so that the liquid layer can be efficiently taken up by cells. In addition, the preparation process is simple and feasible, the biocompatibility is good, and the mucus penetrating carrier can be used.
Patients randomised to the oral nutritional supplement group will continue their normal diet. In addition, this group will commence taking oral nutritional supplement twice daily 5 days prior to surgery and continued for 4 weeks post surgery. Intake of nutritional drink will be suspended during their fasting period prior to surgery and will commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment. Patient adherence to the study protocol with the nutritional supplement regimen will be recorded daily by the patient for four the four weeks the supplement is provided.
Pregnancy Testing

Verify the pregnancy status of females of reproductive potential prior to initiating bosentan, monthly during treatment and one month after stopping treatment with bosentan. The patient should contact her physician immediately for pregnancy testing if onset of menses is delayed or pregnancy is suspected. If the pregnancy test is positive, the physician and patient must discuss the risks to her, the pregnancy, and the fetus.

Contraception

Drug interaction studies show that bosentan reduces serum levels of the estrogen and progestin in oral contraceptives. Based on these findings, hormonal contraceptives (including oral, injectable, transdermal, and implantable contraceptives) may be less effective for preventing pregnancy in patients using bosentan and should not be used as a patient’s only contraceptive method [see Drug Interactions (7.2)]. Females of reproductive potential using bosentan must use two acceptable methods of contraception during treatment and for 1 month after treatment with bosentan. Patients may choose one highly effective form of contraception (intrauterine devices (IUD) or tubal sterilization) or a combination of methods (hormone method with a barrier method or two barrier methods). If a partner’s vasectomy is the chosen method of contraception, a hormone or barrier method must be used along with this method. Counsel patients on pregnancy planning and prevention, including emergency contraception, or designate counseling by another healthcare provider trained in contraceptive counseling [see Boxed Warning].

Infertility

Males

Decreased sperm counts have been observed in patients receiving bosentan. Based on these findings and findings in animals, bosentan may impair fertility in males of reproductive potential. It is not known whether effects on fertility would be reversible [see Warnings and Precautions (5.6), Adverse Reactions (6.1), Nonclinical Toxicology (13.1)].
The EndoVE (Endoscopic vacuum electrode) is moved endoscopically into surface contact with the polyp. A vacuum is employed through the EndoVE as required to assist contact with the device. An electrical field depth of 8-10mm and surface area of 2cm3 is treated per pulse application. The electrical pulses are produced by an electroporation generator (ePORE device). Larger polyps will require multiple applications to ensure the full surface area has been treated. An overlap with previously pulsed areas is preferable to ensure all of the polyp tissue is ablated. The patient will then be transferred to the step-down ward to monitor for any adverse events before being discharged on the same day. The patient will be requested to attend the clinic for an endoscopy follow up at 4-6 weeks post EndoVE polyp treatment to investigate the response.
The utility model relates to a double-layer coating biological active-micro capsule for the nutrients. The exterior of the biological activity substance is coated with the double layer capsule material. The outer capsule material comprises the soybean soluble protein nutrients. The inner capsule material comprises the DHA functional fatty acids. The product is made by the procedures of the solution encapsulation of the inner capsule material, the aqueous solution encapsulation of the outer capsule material, the homogenization, and the drying. The utility model aims to the characteristic of the human body digesting and absorbing the nutrient, takes the desired human body nutrients components as the wall material, generates the functional biological activity microcapsule which conforms to the rule of the digestion and the absorption of the human nutrition and is provided with the structural gradational double-layer coating, avoids the destroying and degradation of the biological activity substances in the digestive tract, causes the biological activity substances to reach the intestinal tract position, and plays the functional action.
Formulations comprising Angiotensin(1-7) and/or derivatives thereof for pharmaceutical use, particularly for administration by inhalation, preferably by nebulisation, are disclosed. In the pharmaceutical compositions, the active principle is present in a solubilized form, together with a hydrophilic surfactant and a non-reducing sugar. Such pharmaceutical compositions may be used in the field of medicine. The formulations have therapeutically and commercially useful concentrations of the active principle. A dried powder obtainable by spray-drying or lyophilizing the pharmaceutical compositions is also disclosed. The pharmaceutical compositions may be obtained by reconstitution in water (or another suitable aqueous solvent) of the dried powder. Kits comprising the pharmaceutical composition and/or the dried powder are also disclosed. Topical application of the formulation (e.g., as eye or nose drops) is also disclosed.
The investigators have performed a step-wise mixed-methods sub-study to investigate current standard of care in the most common settings in Denmark (Sports Physiotherapists mainly from private primary practice, and Orthopedic Surgeons caring for these patients, invited from all public secondary care orthopedic departments in Denmark). Results were then combined with reports from patients seen in the clinic (n=34) who were questioned in detail on what modalities and advice they had previously received. The results were mostly compatible with the recent international survey of clinicians treating Osgood-Schlatter. With the findings from this process the investigators have developed a patient-aimed leaflet, which will contain vignettes and elaborations of the multimodal approaches included in the standardized usual care package, which will be implemented through four visits (at months 0, 1, 2, 3) with a physiotherapist (mirroring the plan of care of the experimental group).